Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Ninjutsu
|
| gptkbp:activities |
inhibits nucleic acid synthesis
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:brand |
Antrypol
Pyridinoline Suramin sodium |
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:composed_of |
reaction with sulfuric acid
reaction with formaldehyde reaction with sodium bicarbonate reaction with sodium carbonate reaction with sodium hydroxide reaction with sodium nitrite reaction with sodium sulfide reaction with sodium sulfite reaction with sodium thiosulfate reaction with sodium bisulfite reaction with thiourea sulfonation of urea |
| gptkbp:contraindication |
severe renal impairment
active bleeding disorders hypersensitivity to suramin |
| gptkbp:developed_by |
German scientists
|
| gptkbp:discovered_by |
1916
|
| gptkbp:dissolved |
water-soluble
|
| gptkbp:excretion |
primarily through urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
suramin
|
| gptkbp:ingredients |
C51 H40 N8 O23 S4
|
| gptkbp:is_atype_of |
P01 B A01
|
| gptkbp:is_used_for |
treatment of certain cancers
treatment of river blindness treatment of African sleeping sickness |
| gptkbp:lifespan |
approximately 40 hours
|
| gptkbp:manager |
IV
|
| gptkbp:metabolism |
not extensively metabolized
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:products |
gptkb:eflornithine
gptkb:melarsoprol gptkb:pentamidine |
| gptkbp:research |
cancer research
antiviral research antiparasitic research |
| gptkbp:side_effect |
headache
nausea fever vomiting skin rash |
| gptkbp:type_of |
147-18-4
|
| gptkbp:weight |
1075.12 g/mol
|